For the year ending 2025-12-31, DAWN had $72,110K increase in cash & cash equivalents over the period. -$104,077K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -107,322 |
| Acquired in-process research and development assets | 0 |
| Share-based compensation expense | 44,388 |
| Depreciation expense | 366 |
| Accretion of discounts on short-term investments, net | 15,738 |
| Amortization of intangible assets | 3,110 |
| Amortization of operating right-of-use asset | 310 |
| Loss from sale of property and equipment | -71 |
| Gain from sale of priority review voucher | 0 |
| Accounts receivable, net | 12,859 |
| Inventory | 2,860 |
| Prepaid expenses and other current assets | -2,481 |
| Deposits and other long-term assets | 109 |
| Accounts payable | 471 |
| Accrued expenses and other current liabilities | -16,010 |
| Deferred revenue | 253 |
| Operating lease liability | -32 |
| Other long-term liability | -277 |
| Net cash used in operating activities | -103,757 |
| Cash paid for purchase of short-term investments | 695,811 |
| Proceeds from maturity of short-term investments | 864,273 |
| Proceeds from sale of short-term investments | 9,974 |
| Cash paid for acquired intangible assets | 3,500 |
| Proceeds from sale of other investments | 0 |
| Cash paid for acquired in-process research and development assets | 0 |
| Cash paid for purchase of property and equipment | 320 |
| Proceeds from sale of property and equipment | 32 |
| Net cash (used in) provided by investing activities | 174,648 |
| Proceeds from issuance of common stock in connection with private placement, net of placement agent fees and offering costs | 0 |
| Proceeds from issuance of prefunded warrants to purchase common stock in connection with private placement, net of issuance costs | 0 |
| Proceeds from issuance of common stock, net | 0 |
| Proceeds from issuance of common stock upon stock option exercises | 126 |
| Proceeds from issuance of common stock upon employee stock purchase plan purchase | 1,093 |
| Cash provided by financing activities | 1,219 |
| Net (decrease) increase in cash and cash equivalents | 72,110 |
| Cash and cash equivalents, beginning of period | 124,968 |
| Cash and cash equivalents, end of period | 197,078 |
Day One Biopharmaceuticals, Inc. (DAWN)
Day One Biopharmaceuticals, Inc. (DAWN)